<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795934</url>
  </required_header>
  <id_info>
    <org_study_id>19-005226</org_study_id>
    <nct_id>NCT04795934</nct_id>
  </id_info>
  <brief_title>Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair</brief_title>
  <acronym>CTIF</acronym>
  <official_title>Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair Combined With Transoral Incisionless Fundoplication Versus Laparoscopic Nissen Fundoplication for Treatment of Gastroesophageal Reflux Disease in Patients Requiring Hiatal Hernia Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EndoGastric Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fox Valley Surgical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Esophageal and Reflux Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-blind randomized control study will follow 142 subjects across 5 sites randomized&#xD;
      on a 1:1 ratio to compare treatment efficacy and safety between TIF and LNF in GERD patients&#xD;
      with hiatal hernia undergoing hernia repair.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Measures will be taken to minimize or avoid bias in the study &quot;masking/blinding procedures.&quot; Neither treatment groups will be advised as to which procedure (TIF or LNF) they will be receiving. Randomization assignment will be recorded in the EDC and subject tracking, but will not be recorded within the EMR to reduce clinical team exposure to their randomized status for follow-up care. Research teams will not be blinded to the randomization results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in HRQL score ≤ 15%</measure>
    <time_frame>6 months</time_frame>
    <description>Hypothesis: TIF is non-inferior to LNF as measured by quality of life at 6 months post-procedure using the Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL) score.&#xD;
GERD-HRQL Scoring Total Score: Calculated by summing the individual scores to questions 1-15.&#xD;
Greatest possible score (worst symptoms) = 75&#xD;
Lowest possible score (no symptoms) = 0&#xD;
Heartburn Score: Calculated by summing the individual scores to questions 1-6 .&#xD;
Worst heartburn symptoms = 30&#xD;
No heartburn symptoms = 0&#xD;
Scores of ≤ 12 with each individual question not exceeding 2 indicate heartburn elimination.&#xD;
Regurgitation Score: Calculated by summing the individual scores to questions 10-15.&#xD;
Worst regurgitation symptoms = 30&#xD;
No regurgitation symptoms = 0&#xD;
Scores of ≤ 12 with each individual question not exceeding 2 indicate regurgitation elimination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AET</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Upper Endoscopy with 72 Hrs BravoPH Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bloating</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Dysphagia, Bloating, &amp; Reflux Symptoms Questionnaire (DBR) Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dysphagia</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Dysphagia, Bloating, &amp; Reflux Symptoms Questionnaire (DBR) Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distensibility index of GE junction</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Endoflip (optional) Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cessation of Proton Pump Inhibitor (PPI) use</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>PPI Use Questionnaire Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing of esophagitis</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Upper Endoscopy with 72 Hrs BravoPH Case Report Form assessing LA Grade system: A, B, C, or D (if present)&#xD;
Grade A One (or more) mucosal break no longer than 5 mm that does not extend between the tops of two mucosal folds Grade B One (or more) mucosal break more than 5 mm long that does not extend between the tops of two mucosal folds Grade C One (or more) mucosal break that is continuous between the tops of two or more mucosal folds but which involve less than 75% of the circumference Grade D One (or more) mucosal break which involves at least 75% of the esophageal circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of hiatal hernia</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Upper Endoscopy with 72 Hrs BravoPH Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hill grade of GE junction</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Upper Endoscopy with 72 Hrs BravoPH Case Report Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>[Time Frame: 6 months]</time_frame>
    <description>Adverse Event Case Report Form</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>GERD</condition>
  <condition>Hiatal Hernia</condition>
  <arm_group>
    <arm_group_label>Laparoscopic Nissen Fundoplication (LNF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo Transoral Incisionless Fundoplication (CTIF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION</intervention_name>
    <description>LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION</description>
    <arm_group_label>Combo Transoral Incisionless Fundoplication (CTIF)</arm_group_label>
    <arm_group_label>Laparoscopic Nissen Fundoplication (LNF)</arm_group_label>
    <other_name>LAPAROSCOPIC NISSEN FUNDOPLICATION</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 22-80 years of age&#xD;
&#xD;
          2. Subjects have GERD with hiatal hernia &lt; 5 cm (defined as maximum ,axial height from&#xD;
             end of the esophagus to diaphragm by any study including upper endoscopy esophagram&#xD;
             and or at time of surgery) and Hill grade III or IV&#xD;
&#xD;
          3. Pathologic reflux while off PPI based on Lyon criteria by either of the following:&#xD;
&#xD;
             3.1. Conclusive evidence for pathologic reflux defined as acid exposure time (AET) &gt;&#xD;
             6% (worst day) or LA grade C or D esophagitis.&#xD;
&#xD;
             3.2. Borderline evidence of pathologic reflux defined as presence of one of the&#xD;
             following parameters: AET 4-6%, LA grade A or B.&#xD;
&#xD;
          4. Commitment to long-term study&#xD;
&#xD;
          5. Ability to give consent individually or by a legally authorized representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hiatal hernia &gt; 5 cm (defined as maximum axial height from end of the esophagus to&#xD;
             diaphragm by any study including upper endoscopy esophagram and or at time of surgery)&#xD;
&#xD;
          2. Evidence of clinically significant major esophageal motility disorder as determined by&#xD;
             the site primary investigator&#xD;
&#xD;
          3. Pregnancy (in females) at time of procedure&#xD;
&#xD;
          4. Previous anti-reflux procedure&#xD;
&#xD;
          5. Subjects requiring mesh treatment at time of procedure&#xD;
&#xD;
          6. At the discretion of the site PI for subject safety&#xD;
&#xD;
          7. BMI &gt; 35 at time of surgery.&#xD;
&#xD;
          8. Prior gastric surgery that may affect ability to perform either procedure or affect&#xD;
             normal gastric function (e.g. gastrectomy, gastric bypass, sleeve gastrectomy,&#xD;
             pyloroplasty.&#xD;
&#xD;
          9. Severe gastroparesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth J Chang, MD</last_name>
      <email>kchang@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Desario</last_name>
      <email>sdesario@hs.uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ninh T Nguyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth J Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John C Lipham, MD</last_name>
      <email>John.Lipham@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pui Yuk Yan</last_name>
      <email>puiyan@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John C Lipham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Esophageal and Reflux Surgery</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>880113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reginald Bell, M.D.</last_name>
      <phone>303-788-7700</phone>
    </contact>
    <contact_backup>
      <last_name>Rachel Heidrick</last_name>
      <phone>303-788-1636</phone>
      <email>rachel@iersurgery.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Hyland, BS</last_name>
      <phone>507-284-4723</phone>
      <email>hyland.erik@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Travis S Fisher</last_name>
      <phone>507-538-7168</phone>
      <email>fisher.travis1@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Barham K Abu Dayyeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reisenauer S Janani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly M Chambers, BSN, RN</last_name>
      <phone>512-495-5773</phone>
      <email>Kelly.Chambers@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>F. P. &quot;Tripp&quot; Buckley III, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik B Wilson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Connie Pollard</last_name>
      <email>Connie.Pollard@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Erik B Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Valley Surgical</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter G Janu</last_name>
      <email>Peter.Janu@fvsawi.com</email>
    </contact>
    <contact_backup>
      <last_name>Wendy</last_name>
      <email>pjanu@new.rr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter G Janu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barham K. Abu Dayyeh, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Hiatal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Health information may be collected from: Past, present and future medical records. Research procedures, including research office visits, tests, interviews and questionnaires. Health information will be used and/or given to others to: Do the research. Report the results. See if the research was conducted following the approved study plan, and applicable rules and regulations. Health information may be used and shared with: Mayo Clinic research staff involved in this study or clinical care. Researchers involved in this study at other institutions. The sponsor of this study and the people or groups hired by the sponsor to help perform this research. The Mayo Clinic Institutional Review Board that oversees the research. Federal and State agencies (such as the Food and Drug Administration, the Department of Health and Human Services, the National Institutes of Health and other United States agencies) or government agencies in other countries that oversee or review research.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

